A Phase 3 interventional study of Ranibizumab and Laser in Diabetic Macular Edema, sponsored by Novartis. Completed at 13 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-04-01.
Sponsored by Novartis · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies testing ranibizumab in Edema — none open to participants now, none under way, none of them phase 3. Ranibizumab · Edema.
Among the 13 studies testing ranibizumab in Edema, this one is the 4th largest by enrollment, is one of 2 that started in 2008, is one of 5 in phase 3, and was the 4th registered.
568 studies on the registry are indexed under Edema; 97 are open to participants now.
Browse Edema studies →None of the 13 studies testing ranibizumab in Edema is open now. The open studies under Edema, anywhere →
Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 56 Edema studies recruiting now, 34 (61%) set no upper age limit and 16 (29%) stop at 75 or younger; 8 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 5 · Phase 4 3
First in 2007; this study’s year is marked. 2 started in 2008.
This study's enrollment of 345 is above the median of 54 across 402 interventional studies indexed under Edema.
Median enrollment 50 across the 13 interventional studies. Of the 11 that completed or were terminated, 6 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 13 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
Novartis has 4 studies filed under Edema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies testing ranibizumab in Edema, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CRFB002D2301: The core study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or mono-therapy in patients with visual impairment due to diabetic macular edema.
CRFB002D2301E1: A 24 month open-label extension study for participants who completed the 12 month core study evaluated the long-term safety and efficacy of ranibizumab (0.5 mg) as symptomatic treatment for visual impairment due to diabetic macular edema.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Extension Inclusion Criteria:
-Completion of the Core Study
Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met: Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits. Patients also received sham laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician. Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes. In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy.
Drug: Ranibizumab · Procedure: Laser · Procedure: Sham laser
Ranibizumab 0.5 mg was administered monthly by intravitreal injection in the study eye for 3 months. After the third injection, treatment was suspended if either one of the following criteria was met: Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits. Patients also received active laser treatment on Day 1 and subsequently at intervals of at least 3 months, if deemed necessary by the evaluating physician. Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes. In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy.
Drug: Ranibizumab · Procedure: Laser
Laser photocoagulation treatment was administered on Day 1 and at intervals of at least 3 months, if deemed necessary by the physician. Patients also received monthly sham intravitreal injection in the study eye for 3 consecutive months. After the third injection, treatment was suspended if either one of the following criteria was met: Improvement in best corrected visual acuity (BCVA) could not be attributed to treatment at the last 2 visits, in the opinion of the investigator, or BCVA \> 84 letters (approximate Snellen equivalent of 20/20) was observed at the last 2 last visits. Active/sham laser treatment was always administered before (sham) intravitreal injections. The minimum interval between the 2 treatments was 30 minutes. In the extension study at the investigator's discretion, patients received open-label ranibizumab 0.5 mg intravitreal injections once a month until stable vision was reached (a maximum of 24 injections) and could receive laser therapy.
Drug: Ranibizumab · Procedure: Laser · Drug: Sham to ranibizumab
0.5 mg ranibizumab administered by intravitreal injection.
Laser photocoagulation treatment
Sham to laser procedure.
Sham to ranibizumab administered as an intravitreal injection.
Core Study: Difference Between the Baseline Level of Visual Acuity (Letters) of the Study Eye and the Mean Visual Acuity Averaged Over All Monthly Post-baseline Assessments From Month 1 to Month 12
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Baseline through the end of study (Month 12)
Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 24 Month Extension Study
Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.
Time frame: Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]
Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 24 Month Extension Study
Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.
Time frame: Extension baseline (Month 12 -end of core study) to Month 36 (end of extension study) [24 Months]
Core Study: Categorized Change in Visual Acuity (Letters) of the Study Eye From Baseline at Month 12
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Baseline to Month 12
Core Study: Mean Change From Baseline in Visual Acuity (Letters) of the Study Eye Over Time
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
Time frame: Baseline to Month 12
Core Study: Mean Change From Baseline at Month 12 in Central Retinal Thickness of the Study Eye
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation.
Time frame: Baseline to Month 12
Core Study: Mean Change From Baseline in Patient-reported Visual Functioning
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.
Time frame: Baseline to Month 12
Extension Study: Percentage of Participants With Ocular Adverse Events (AEs) in the Study Eye in the 36 Months of the Core and Extension Studies
Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.
Time frame: Core baseline (Day 1 of the core study) to Month 36 (end of extension study) [36 months]
Extension Study: Percentage of Participants With Non-Ocular Adverse Events (AEs) in the 36 Months of the Core and Extension Studies
Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about Adverse Events can be found in the Adverse Event section.
Time frame: Core baseline (Day 1 of the core study) to Month 36 (end of extension study) [36 Months]
Extension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.
Time frame: Extension baseline (Month12 -end of core study), Month 36 (end of extension study)
Extension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.
Time frame: Core baseline (Day 1 of the core study), Month 36 (end of extension study)
| Milestone | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Started | 116 | 118 | 111 |
| Completed | 102 | 103 | 98 |
| Not completed | 14 | 15 | 13 |
| Withdrew: Adverse event | 5 | 3 | 3 |
| Withdrew: Abnormal laboratory value(s) | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 4 | 7 | 7 |
| Withdrew: Lost to follow-up | 0 | 1 | 0 |
| Withdrew: Death | 2 | 2 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 0 |
| Milestone | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Started | 83 | 83 | 74 |
| Did not receive ranibizumab in extension | 16 | 21 | 15 |
| Completed | 73 | 72 | 63 |
| Not completed | 10 | 11 | 11 |
| Withdrew: Adverse event | 2 | 2 | 2 |
| Withdrew: Subject withdrew consent | 3 | 4 | 4 |
| Withdrew: Lost to follow-up | 2 | 1 | 2 |
| Withdrew: Administrative problems | 1 | 1 | 0 |
| Withdrew: Death | 2 | 3 | 3 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
| Letters | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Baseline | 64.7 ± 10.07 | 63.4 ± 9.99 | 62.6 ± 11.01 |
| Average Month 1 to month 12 | 70.8 ± 10.53 | 69.2 ± 11.44 | 63.4 ± 12.26 |
| Change from Baseline | 6.1 ± 6.43 | 5.9 ± 7.92 | 0.8 ± 8.56 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
| Participants | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Gain of ≥ 10 letters | 43 | 51 | 17 |
| Loss of ≥ 10 letters | 4 | 5 | 14 |
| Gain of ≥ 15 letters | 26 | 27 | 9 |
| Loss of ≥ 15 letters | 1 | 4 | 9 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters.
| Letters | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Month 1 | 2.9 ± 0.49 | 3.1 ± 0.56 | 0.5 ± 0.64 |
| Month 2 | 4.4 ± 0.64 | 4.9 ± 0.56 | 0.4 ± 0.84 |
| Month 3 | 5.9 ± 0.65 | 5.8 ± 0.65 | -0.5 ± 0.92 |
| Month 4 | 5.3 ± 0.68 | 5.4 ± 0.69 | 0.5 ± 0.92 |
| Month 5 | 5.9 ± 0.68 | 5.7 ± 0.76 | 0.9 ± 0.88 |
| Month 6 | 6.7 ± 0.68 | 6.2 ± 0.78 | 0.9 ± 0.94 |
| Month 7 | 7.0 ± 0.72 | 6.5 ± 0.84 | 1.1 ± 0.98 |
| Month 8 | 7.1 ± 0.75 | 6.4 ± 1.06 | 1.3 ± 0.96 |
| Month 9 | 6.8 ± 0.76 | 6.8 ± 1.05 | 1.4 ± 0.90 |
| Month 10 | 7.3 ± 0.77 | 6.4 ± 1.04 | 0.8 ± 1.00 |
| Month 11 | 6.9 ± 0.79 | 6.8 ± 1.10 | 1.4 ± 0.95 |
| Month 12 | 6.8 ± 0.77 | 6.4 ± 1.08 | 0.9 ± 1.09 |
Retinal thickness was measured using Optical Coherence Tomography (OCT). The images were reviewed by a central reading center to ensure a standardized evaluation.
| Micrometers | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Baseline | 427.1 ± 118.42 | 416.4 ± 119.91 | 412.4 ± 124.53 |
| Value at Month 12 | 308.4 ± 112.26 | 288.2 ± 90.11 | 351.1 ± 139.91 |
| Change from Baseline | -118.7 ± 115.07 | -128.3 ± 114.34 | -61.3 ± 132.29 |
The National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) was used to measure a patient's subjective assessment of vision-related quality of life. The 12 subscales in the VFQ-25 are general health, general vision, ocular pain, near activities, distance activities, social function, mental health, role difficulties, dependency, driving, color vision, and peripheral vision. The scores on the subscales were added together for a total score, which ranged from 0 to 100. A higher score indicated improvement in quality of life due to vision function.
| Units on a scale | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser |
|---|---|---|---|
| Baseline | 72.8 ± 16.91 | 74.1 ± 18.06 | 73.5 ± 18.18 |
| Month 12 | 77.8 ± 19.19 | 79.5 ± 17.29 | 74.1 ± 18.80 |
| Change from Baseline | 5.0 ± 12.97 | 5.4 ± 11.14 | 0.6 ± 12.56 |
Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.
| Percentage of participants | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser With Ranibizumab in Extension | Laser Without Ranibizumab in Extension |
|---|---|---|---|---|
| Adverse Events | 56.6 | 56.6 | 52.5 | 40.0 |
| Serious Adverse Events | 2.4 | 1.2 | 1.7 | 0.0 |
Participants with ocular (occurring in the eye) serious adverse events (SAEs) and non-serious AEs in the study eye. The study eye is the eye that received the treatment. AEs are the appearance or worsening of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.
| Percentage of participants | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser With Ranibizumab in Extension | Laser Without Ranibizumab in Extension |
|---|---|---|---|---|
| Adverse Events | 66.3 | 67.5 | 64.4 | 46.7 |
| Serious Adverse Events | 2.4 | 3.6 | 5.1 | 0.0 |
Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about Adverse Events can be found in the Adverse Event section.
| Percentage of participants | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser With Ranibizumab in Extension | Laser Without Ranibizumab in Extension |
|---|---|---|---|---|
| Adverse Events | 83.1 | 81.9 | 84.7 | 73.3 |
| Serious Adverse Events | 36.1 | 37.3 | 42.4 | 13.3 |
Participants with non-ocular (not occurring in the eye) serious adverse events (SAEs) and non-serious AEs. AEs are the appearance or worsening of of any undesirable sign, symptom, or medical condition occurring after starting the study drug even if the event is not considered to be related to study drug. A serious adverse event is defined as an event that is fatal or life-threatening, results in persistent or significant disability/incapacity, constitutes a congenital anomaly/birth defect, requires inpatient hospitalization or prolongation of existing hospitalization or is medically significant. Additional information about adverse events can be found in the Adverse Event section.
| Percentage of participants | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser With Ranibizumab in Extension | Laser Without Ranibizumab in Extension |
|---|---|---|---|---|
| Adverse Events | 73.5 | 73.5 | 71.2 | 73.3 |
| Serious Adverse Events | 27.7 | 30.1 | 37.3 | 13.3 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.
| Letters | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Active Laser |
|---|---|---|---|
| Extension Study: Mean Change From Extension Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36 | 0.1 ± 9.10 | -0.5 ± 9.19 | 3.7 ± 6.88 |
Visual acuity (VA) was assessed on both eyes during every study visit using best correction determined from protocol refraction. VA measurements (number of letters correctly identified) were performed with the patient in a sitting position using Early Treatment Diabetic Retinopathy Study (ETDRS)-like visual acuity testing charts at a testing distance of 4 meters. An increase in the number of letters read correctly indicates improvement.
| Letters | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Active Laser |
|---|---|---|---|
| Extension Study: Mean Change From Core Study Baseline in Best Corrected Visual Acuity (BCVA) at Month 36 | 8.0 ± 10.09 | 6.7 ± 9.59 | 6.0 ± 9.35 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ranibizumab 0.5 mg | — | 41/115 (35.7%) | 79/115 (68.7%) |
| Ranibizumab 0.5 mg + Laser | — | 43/120 (35.8%) | 83/120 (69.2%) |
| Laser With Ranibizumab in Extension | — | 28/59 (47.5%) | 50/59 (84.7%) |
| Laser Without Ranibizumab in Extension | — | 7/51 (13.7%) | 31/51 (60.8%) |
| Event | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser With Ranibizumab in Extension | Laser Without Ranibizumab in Extension |
|---|---|---|---|---|
| Cardiac failureCardiac disorders | 1/115 | 1/120 | 4/59 | 1/51 |
| Myocardial infarctionCardiac disorders | 1/115 | 4/120 | 3/59 | 0/51 |
| PneumoniaInfections and infestations | 0/115 | 1/120 | 3/59 | 0/51 |
| Diabetic footMetabolism and nutrition disorders | 2/115 | 0/120 | 3/59 | 1/51 |
| Acute myocardial infarctionCardiac disorders | 1/115 | 0/120 | 2/59 | 0/51 |
| Cataract (Study eye)Eye disorders | 0/115 | 3/120 | 2/59 | 0/51 |
| Angina pectorisCardiac disorders | 3/115 | 1/120 | 0/59 | 0/51 |
| Coronary artery diseaseCardiac disorders | 3/115 | 1/120 | 1/59 | 0/51 |
| FallInjury, poisoning and procedural complications | 3/115 | 0/120 | 0/59 | 0/51 |
| Cerebrovascular accidentNervous system disorders | 3/115 | 1/120 | 1/59 | 0/51 |
| Event | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser With Ranibizumab in Extension | Laser Without Ranibizumab in Extension |
|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/115 | 21/120 | 15/59 | 8/51 |
| Eye pain (Study eye)Eye disorders | 15/115 | 11/120 | 13/59 | 2/51 |
| Diabetic retinal oedema (Fellow eye)Eye disorders | 12/115 | 19/120 | 11/59 | 3/51 |
| Cataract (Study eye)Eye disorders | 9/115 | 17/120 | 9/59 | 4/51 |
| InfluenzaInfections and infestations | 12/115 | 8/120 | 8/59 | 5/51 |
| Back painMusculoskeletal and connective tissue disorders | 7/115 | 5/120 | 8/59 | 1/51 |
| HypertensionVascular disorders | 15/115 | 11/120 | 6/59 | 6/51 |
| Cataract (Fellow eye)Eye disorders | 10/115 | 12/120 | 7/59 | 5/51 |
| Conjunctival haemorrhage (Study eye)Eye disorders | 9/115 | 13/120 | 0/59 | 0/51 |
| Conjunctival hyperaemia (Study eye)Eye disorders | 9/115 | 8/120 | 5/59 | 2/51 |
| Age Continuous(years) | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser | Total |
|---|---|---|---|---|
| Mean | 62.9 ± 9.29 | 64.0 ± 8.15 | 63.5 ± 8.81 | 63.5 ± 8.75 |
| Age, Customized(Participants) | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser | Total |
|---|---|---|---|---|
| < 55 years | 24 | 14 | 13 | 51 |
| 55 - <65 years | 41 | 42 | 53 | 136 |
| 65 - <75 years | 40 | 53 | 31 | 124 |
| >=75 years | 11 | 9 | 14 | 34 |
| Sex: Female, Male(Participants) | Ranibizumab 0.5 mg | Ranibizumab 0.5 mg + Laser | Laser | Total |
|---|---|---|---|---|
| Female | 43 | 48 | 53 | 144 |
| Male | 73 | 70 | 58 | 201 |
The record gives a start of May 2008, a primary completion of Jan 2010 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ranibizumab